Lei Xiao

Director Ejecutivo en Innovative Cellular Therapeutics Co., Ltd. .

Health Technology

Perfil

Lei Xiao is the founder of Innovative Cellular Therapeutics Co., Ltd.
He holds the titles of Chairman, Chief Executive, and Scientific Officer, which he has held since the company's founding in 2009.

Cargos activos de Lei Xiao

Empresas	Cargo	Inicio
Innovative Cellular Therapeutics Co., Ltd. Innovative Cellular Therapeutics Co., Ltd. BiotechnologyHealth Technology Innovative Cellular Therapeutics Co., Ltd. is a Chinese private clinical stage biotechnology company headquartered in an undisclosed location. Innovative Cellular Therapeutics is focused on the development of cellular immunotherapies for the treatment of solid tumors, using their unique CoupledCAR® technology platform. The company has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and prostate cancer, and has a broad pipeline of CAR-T candidates targeting additional solid tumors. The company was founded in 2009 by Zhao Wu and Lei Xiao, with Lei Xiao serving as the CEO since then.	Director Ejecutivo	01/01/2009

Todos los cargos activos de Lei Xiao

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Lei Xiao.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	1
Innovative Cellular Therapeutics Co., Ltd. Innovative Cellular Therapeutics Co., Ltd. BiotechnologyHealth Technology Innovative Cellular Therapeutics Co., Ltd. is a Chinese private clinical stage biotechnology company headquartered in an undisclosed location. Innovative Cellular Therapeutics is focused on the development of cellular immunotherapies for the treatment of solid tumors, using their unique CoupledCAR® technology platform. The company has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and prostate cancer, and has a broad pipeline of CAR-T candidates targeting additional solid tumors. The company was founded in 2009 by Zhao Wu and Lei Xiao, with Lei Xiao serving as the CEO since then.	Health Technology